Knifsend Robin 4
4 · CytomX Therapeutics, Inc. · Filed Jun 4, 2019
Insider Transaction Report
Form 4
Knifsend Robin
Principal Accounting Officer
Transactions
- Award
Common Stock
2019-05-31$8.21/sh+1,812$14,878→ 2,791 total
Footnotes (1)
- [F1]1,812 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).